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Abstract Specific inhibitors for cathepsin L and cathepsin S
have been developed with the help of computer-graphic modeling
based on the stereo-structure. The common fragment, N-(L-
trans-carbamoyloxyrane-2-carbonyl)-phenylalanine-dimethyl-
amide, is required for specific inhibition of cathepsin L. Seven
novel inhibitors of the cathepsin L inhibitor Katunuma (CLIK)
specifically inhibited cathepsin L at a concentration of 1037 M in
vitro, while almost no inhibition of cathepsins B, C, S and K was
observed. Four of the CLIKs are stable, and showed highly
selective inhibition for hepatic cathepsin L in vivo. One of the
CLIK inhibitors contains an aldehyde group, and specifically
inhibits cathepsin S at 1037 M in vitro.
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1. Introduction
Several mammalian lysosomal cysteine proteases, such as
cathepsins B, H, L, S, C and K, have been well characterized.
Speci¢c inhibitors of individual cathepsins would be powerful
tools for clarifying the di¡erent functions of each cathepsin.
An irreversible speci¢c inhibitor of cysteine proteases, derived
from epoxysuccinate, was ¢rst isolated by Hanada et al. and
named E-64 [1]. This E-64, however, inhibits all cysteine pro-
teases except cathepsin C. Derivatives of L-trans-epoxysuccin-
yl-Ile-Pro derivatives were synthesized by Katunuma et al., in
which the right side chain of the dipeptides was changed from
the leucylagmatine of E-64 to isoleucylproline, named CA-030
and CA-074, showed strict speci¢c inhibition of cathepsin B
[2^5]. However, speci¢c inhibitors for cathepsin L and cathep-
sin S have not been reported. New derivatives of L-trans-
epoxysuccinate and aldehyde were designed as speci¢c inhib-
itors of cathepsins L and S based on the di¡erences in their
substrate binding pockets using computer-graphic analysis.
They were named the cathepsin L inhibitor Katunuma
(CLIK) series, and were chemically synthesized. The chemical
structures are shown in Fig. 1. The inhibitory selectivities were
tested in vitro and in vivo.
2. Materials and methods
2.1. Materials
All epoxysuccinate derivatives of the CLIK group were synthesized
in our laboratory by methods previously described for E-64 and CA-
074, with some modi¢cations [5,6]. They were fully characterized by
infrared spectroscopy (IR), proton-nuclear magnetic resonance spec-
troscopy (proton-NMR) and fast atom bombardment mass spec-
troscopy (MS), and gave single spots on TLC. CLIK-060, N-{L-3-
trans[(1-phenylcarbamoyl-5-amino) pentylcarbamoyl]oxirane-2-car-
bonyl}-L-phenylalanine-dimethylamide hydrochloride, was synthe-
sized in ¢ve steps. The condensation of Ne-acetyl-NK-benzoyl-L-lysine
and L-phenylalaninol with 1-ethyl-3-(3-dimethylaminopropyl)-carbo-
diimide hydrochloride and 1-hydroxy benzotriazole yielded Nc-Ace-
tyl-NK-benzolyl-L-phenylalaninol, which was oxidized by sulfur triox-
ide pyridine complex in DMSO to yield the desired compound with
m.p. 128^130‡C. Computer graphics were used to analyze the binding
of CLIKs with cathepsin L using the method for analyzing cathepsin
B-CA-030 complex [3,7] and the structure of cathepsin L [8]. The
programs used were QUANTA Version 4.1 and CHARMM Version
23.1, Molecular Simulation, San Diego, CA, USA and MAIN [9].
2.2. Cathepsin assays in vitro and in vivo
Rat liver cathepsins B, L and C were puri¢ed as reported previously
[10^13] and recombinant human cathepsins S [14] and K were ex-
pressed by Escherichia coli and Sf21 insect cells and were puri¢ed
by the methods of Inaoka and Bossard, respectively [15,16]. Cathepsin
activities were assayed with Z-Arg-Arg-MCA for cathepsin B, and Z-
Phe-Arg-MCA for cathepsins L, S, K and C using the method de-
scribed by Barrett and Kirschke [17]. Intracellular cathepsin L activity
was assayed in mice splenocytes (106 cells/ml) incubated with inhib-
itors in Hanks bu¡er for 3 h at 37‡C, and cathepsin L activity in the
mitochondrial-lysosomal (ML) fraction was assayed by Inubushi’s
method [18]. Selective inhibition of intracellular cathepsin L in mouse
liver was assayed by intraperitoneal injection of the inhibitors. At
45 and 120 min after injection, the ML fraction was prepared and
the individual cathepsin activities were assayed.
2.3. Separation and determination of degradative products of CLIKs by
high performance liquid chromatography (HPLC)
After 0.1 mM of each CLIK was incubated with organ homogenate
at 37‡C for 1 h at pH 5.5, the reactions were stopped by methanol.
The remaining CLIKs and degradation products were separated by
HPLC using an Inertsil ODS-3 column (4.6^150 mm), a mixture of
75% 10 mM (pH 6.0) phosphate bu¡er and 25% acetonitrile was used
for the elution phase. CLIKs-088, -112 and -121 were converted to
common products of CLIK-079 through enzymatic degradation by
organ homogenates. The degradation product, CLIK-079, was sepa-
rated from the original compounds in di¡erent eluted fractions from
the column.
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3. Results
3.1. Essential structure of CLIK group for selective inhibition
of cathepsin L
The following two CLIK groups for inhibition of cathepsin
L and cathepsin S were developed and their chemical struc-
tures are shown in Fig. 1. CLIK group [I] is composed of
CLIKs-066, -088, -112, -121, -148, -181 and -195, these inhib-
itors share the common essential structure, N-(trans-carba-
moyloxyrane-2-carbonyl)-L-phenylalanine-dimethylamide, for
forming a thioether speci¢cally with the active site cysteine-
SH of cathepsin L. Only CLIK-066 contains a lysine residue
attached to the epoxysuccinate fragment. The characteristic
aromatic derivatives in the left hand domain are bound di-
rectly to the epoxysuccinate-amide of the common fragment.
CLIK-112, which is an S-S stereo-structure speci¢c for epox-
ysuccinate rings, showed strong inhibition of cathepsin L, but
CLIK-141, which is the R-R stereo-isomer of CLIK-112,
showed no inhibition, indicating that the S-S stereo-structure
is required for inhibition of cathepsin L. CLIK-060 and
CLIK-172 in group [II] contain an aldehyde group at the right
hand end of the molecule as a binding radical to the cysteine -
SH of cathepsin S, as shown in Fig. 1, panel [II]. CLIK-172, a
stereo-isomer of CLIK-060, showed some speci¢city for ca-
thepsin S, but the inhibition potency for cathepsin S was
weak. CLIK-173, in which the aldehyde of CLIK-060 mole-
Fig. 1. Essential common structure for expression of speci¢c inhibition of cathepsin L and cathepsin S. The essential common structure for spe-
ci¢city to cathepsin L inhibition is illustrated in the enclosed circle in the CLIK group [I]. Group [II], CLIK-060, shows speci¢city for cathepsin
S. The aldehyde residue is located in the right end domain, and is available to react with -SH of cathepsin S.
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cule is replaced by alcohol, showed no inhibition. Therefore,
the aldehyde might be the active group reacting with the -SH
of cathepsin S to form a semithioacetal.
3.2. Selective inhibition for puri¢ed cathepsin L and cathepsin S
by CLIK groups in vitro
Selective inhibition pro¢les of CLIK groups for various
cathepsins are compared in Table 1. CLIK group [I],
CLIKs-066, -088, -112, -121, -148, -181 and -195, speci¢cally
inhibited cathepsin L, at 1037 M, while no inhibition of ca-
thepsins B and C was observed at 1036 M, and CLIKs-148,
-181 and -195 inhibited cathepsins S and K at 1035 M. CLIK-
060 in group [II] exhibited strong speci¢city for cathepsin S at
a concentration of 1037 M, although almost no inhibition of
cathepsins B, L, K and C was observed at 1036 M.
3.3. Degradation of some of the CLIK group [I] by enzymes in
liver and small intestine and changes in inhibitory
speci¢cities
CLIK group [I] is stable in phosphate bu¡er at pH 4.0V8.0
for 24 h at room temperature. Enzymatic degradation of the
CLIKs was calculated from the residual percentage of their
original compounds, as Fig. 2 shows. The small intestine and
liver were homogenized with three volumes of potassium
phosphate bu¡er (KPB) of pH 5.5 and sonicated. Some of
the CLIK group [I] inhibitors were degraded by an unknown
organ enzyme. CLIKs-066, -148, -181 and -195 showed strong
resistance to the enzymatic degradation, therefore, they have
the potential to be used as stable and speci¢c inhibitors in
vivo. CLIKs-088, -112 and -121 were degraded and formed
the common product, CLIK-079, which showed no inhibitory
selectivity for cathepsin L, but also decreased the inhibitory
potency for cathepsin L. This enzymatic degradation was in-
hibited by co-addition of chymostatin (data not shown).
3.4. Selective inhibition of lysosomal cathepsin L in cultured
splenocytes and liver in vivo
Selective inhibition of cathepsin L was tested in mice hep-
atic lysosomes by intraperitoneal injection of CLIK-148, -181
or -195 in vivo, and also in cultured mice splenocytes. The
cathepsin L activity in the ML fraction of cultured splenocytes
in Hanks medium with and without inhibitor was assayed
after a 3 h incubation. A 50% inhibition of cathepsin L activ-
ity in the splenocytes was observed by addition of 1036 M
CLIK-148 or -195 into the medium, almost complete inhib-
ition was observed by 1035 M. At 45 and 120 min after intra-
peritoneal injection of 3 mg/kg of CLIK-148, -181 or -195, the
activities of cathepsins B and L in hepatic ML fractions were
assayed, cathepsin L was inhibited selectively as illustrated in
the upper panel of Fig. 3, while cathepsin B activity was not.
Table 1
Selective inhibition pro¢le of CLIKs for various cathepsins in vitro
CLIK
No.
10x M Inhibition of cathepsins (%) Usable
for
B L K S C
CLIK [I] 066 35 0 100 27 28 0
36 100 11 0 in vitro
37 76 0 in vivo
38 26
088 35 0 100 23 64 17 in vitro
36 79 15 0 0
37 30 0
112 35 6 100 50 77 15 in vitro
36 0 100 30 14 0
37 100 10 0 0
38 90 0
39 30 0
121 35 15 100 25 100 29 in vitro
36 0 100 17 72 0
37 74 0 35
38 41 0 10
148 35 0 100 40 100 35
36 100 0 30 0 in vitro
37 63 0 in vivo
38 20
181 35 0 100 90 80 50
36 100 15 10 5 in vitro
37 80 0 0 0 in vivo
38 50
195 35 20 100 80 100 40
36 0 100 0 25 0 in vitro
37 80 0 in vivo
38 20
39 0
CLIK [II] 60 36 25 30 10 100 13
37 0 0 0 86 7 in vitro
38 40 0 in vivo
39 0
CLIK group [I] : CLIKs-066, -088, -112, -121, -148, -181 and -195
are speci¢c inhibitors for cathepsin L. CLIK [II] is a speci¢c inhibi-
tor for cathepsin S. Rat liver cathepsin B, L and C were puri¢ed as
reported previously [10^13] and recombinant human cathepsins S
and K were expressed by E. coli and Sf21 insect cells and puri¢ed
according to the method of Zhao and Inaoka, respectively [14^16].
Cathepsin activities were assayed using Z-Phe-Arg-MCA as the sub-
strate by the method of Barrett and Kirschke [17].
Fig. 2. Stability of CLIK group [I] in the presence of enzymes from
liver and small intestine. Each inhibitor (0.1 mM) was incubated
with mouse organ homogenates at 37‡C for 1 h (pH 5.5), and the
reaction was stopped by adding three volumes of methanol. The re-
maining original compound and the product formed, CLIK-079,
were separated and assayed by HPLC.
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CLIK-195 inhibited cathepsin L in a dose dependent manner
at 120 min after injections of 1, 3 or 10 mg/kg inhibitor, as
shown in the lower panel of Fig. 3. Therefore, CLIKs-148, -
181 and -195 were e¡ectively incorporated into the lysosomes
and showed powerful selective inhibition of hepatic intralyso-
somal cathepsin L in vivo.
4. Discussion
The design of CLIK series inhibitors was based on struc-
tural and kinetic data. The crystal structures of papain-E-64
have shown that E-64 binds along the protein surface in the
reverse direction to the peptide chain of substrate analogues in
the non-prime site [19,20]. The crystal structure of cathepsin B
[7] and the complex between CA-030 and cathepsin B [3]
showed that an epoxysuccinyl analogue can also bind to the
prime site of a cysteine protease active site cleft, leading to the
obvious suggestion that an epoxysuccinyl fragment can be
used as a building block that enables access to both the prime
and non-prime substrate binding sites, in contrast to chloro-
methyl, £uoromethyl or aldehyde based inhibitors that bind
only the non-prime subsites. Cathepsin B is the only papain
Fig. 3. Selective inhibition of cathepsins B and L in hepatic ML fraction by intraperitoneal injection of CLIK-148, -181 or -195. Each inhibitor
(3 mg/kg) was injected intraperitoneally into mice. At 45 or 120 min after injection, hepatic ML fractions were prepared. The supernatants of
the sonicated ML fractions were used as enzyme samples. The vertical axis illustrates the % remaining activities, calculated as 100% in the case
without inhibitor. Inubushi’s selective inhibition method for cathepsins B and L was used [18]. The upper panel illustrates the selective inhibi-
tion of hepatic cathepsins B and L by CLIK-148, -181 or -195. The lower panel shows the dose-dependent inhibition of hepatic cathepsin L by
administration of 1.0, 3.0 or 10.0 mg/kg of CLIK-195.
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superfamily protease that contains an occluding loop from Ile-
105 to Glu-112. The carboxyl group of CA-030 or C-terminus
of substrates is locked by His-110 and His-111 on the loop.
CLIKs were designed not to inhibit cathepsin B using the
structural information. With the help of molecular models
and, when they became available, crystal structures of ca-
thepsins L [8] and K [21,22], binding pockets on the surface
of cathepsins were compared and utilized in the design of the
CLIK series. The modeling studies suggested that the frag-
ment of CLIK group [I] can presumably ¢t optimally in the
S2 non-prime site of the protease, whereas the selectivity of
the series is achieved by the fragments extending into the
prime binding region. As seen from Table 1, the CLIK group
[I] compounds exhibit better selectivity of cathepsin L than
cathepsins B and C, having an exopeptidase nature, than
against endopeptidase cathepsins S and K. The speci¢city of
the CLIK group [I] for cathepsin L is thus achieved by the
rigidity and bulkiness of the phenyl-ring attached directly to
the amino group of the common fragment. Recently we de-
termined the crystal structure of the papain-CLIK-148 com-
plex [23]. The structure con¢rmed that the phenyl-ring occu-
pied the S2 non-prime site, and that the N-terminal pyridine-
ring was located in the prime site by an aromatic-aromatic
interaction with the Trp-177. The CLIK group [I] series of
cathepsin L inhibitors and CLIK group [II] type of cathepsin
S inhibitors constitute novel selective tools for investigating
the role of these enzymes in various physiological processes
and disease states.
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